Knee Osteoarthritis Presents $26 Billion Commercial Opportunity Across Major Markets by 2036
Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Knee Osteoarthritis - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
The global knee osteoarthritis market is positioned for sustained growth as aging populations, rising diagnosis rates, demand for non-surgical treatments, and advances in disease-modifying and regenerative therapies reshape patient care. According to the report, the market across the seven major markets (7MM) - the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan - was valued at approximately USD 15.50 billion in 2025. It is projected to reach nearly USD 26 billion by 2036, representing a compound annual growth rate of approximately 5% from 2026 to 2036.
Key Knee Osteoarthritis Market Insights
Market Growth Drivers and Treatment Trends
The expansion of the knee osteoarthritis therapeutics market is being driven by increasing disease prevalence, longer life expectancy, and a growing population of adults over age 50. Greater awareness, improved diagnosis, and the substantial effect of chronic joint pain on mobility and quality of life are also increasing demand for effective long-term treatment.
Clinical practice continues to shift toward minimally invasive and non-surgical procedures. Intra-articular corticosteroids, hyaluronic acid injections, platelet-rich plasma procedures, nonsteroidal anti-inflammatory drugs, and other symptom-management approaches remain important components of care. Localized therapies are gaining attention because they can provide targeted pain control while potentially limiting systemic exposure.
Approved intra-articular products, including JOYCLU, TRILURON, and ZILRETTA, anchor the current competitive landscape. JOYCLU combines hyaluronic acid and diclofenac and is administered by intra-articular injection once every four weeks. TRILURON is delivered through a three-injection intra-articular regimen for patients whose pain is not adequately controlled with conservative care and simple analgesics. ZILRETTA uses PLGA microspheres to provide sustained intra-articular release of triamcinolone acetonide for extended management of inflammation and pain. A single 32 mg extended-release ZILRETTA injection is reported to cost approximately USD 692.
Emerging Knee Osteoarthritis Pipeline
The knee osteoarthritis pipeline is moving beyond symptomatic pain management toward potential disease-modifying, cartilage-preserving, and regenerative approaches. Prominent developers include Paradigm Biopharma, Amzell, CellSeed, Biosplice, Genascence, and other pharmaceutical and biotechnology companies.
Key clinical-stage candidates include ZILOSUL from Paradigm Biopharma, AMZ001 from Amzell, CLS2901C from CellSeed, lorecivivint from Biosplice, and GNSC-001 from Genascence. ZILOSUL, also known as pentosan polysulfate sodium, is being evaluated for its anti-inflammatory and tissue-regenerative potential. Late-stage candidates such as lorecivivint and AMZ001 are expected to increase competition during the forecast period.
Epidemiology and Unmet Medical Needs
Knee osteoarthritis represents a growing clinical and economic burden across the 7MM. In the United Kingdom, almost 10% of adults have received a clinical osteoarthritis diagnosis, compared with approximately 11.5% in the United States and an estimated global prevalence of around 16%. The number of osteoarthritis cases in the UK has continued to rise.
Important unmet needs include improved patient phenotyping and stratification for clinical trials, therapies with fewer adverse effects, greater understanding of disease progression, and treatments capable of delivering durable improvements in pain, mobility, and joint structure. The effect of knee osteoarthritis on quality of life also supports demand for therapies that can delay or reduce the need for surgery.
Knee Osteoarthritis Market Outlook
Market growth through 2036 will depend on clinical efficacy, safety, administration frequency, route of administration, pricing, reimbursement, and the ability of emerging therapies to demonstrate meaningful advantages over established treatments. JOYCLU and ZILRETTA are expected to achieve continued uptake due to localized delivery and sustained pain relief, while TRILURON is anticipated to maintain adoption as a viscosupplementation option.
The report evaluates therapy uptake, peak patient share, revenue potential, market access, pricing trends, treatment switching, real-world prescribing, and competitive positioning. It also examines glycosaminoglycan-based treatments and small-molecule therapies, including their roles in joint lubrication, inflammation control, pain reduction, and sustained intra-articular delivery.
Competitive Landscape and Leading Companies
Report Coverage
The report provides historical and forecast epidemiology, knee osteoarthritis market size and share, patient population forecasts, treatment practices, clinical development analysis, pipeline profiles, pricing and analogue assessments, and therapy adoption forecasts from 2022 through 2036. Geographic coverage includes the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.
Additional analysis includes SWOT assessment, conjoint analysis, treatment-addressable market estimates, patient journey evaluation, unmet-needs assessment, and insights from key opinion leaders and subject-matter experts. More than 10 experts were contacted, with interviews conducted with over six specialists across the 7MM, including professionals affiliated with institutions such as the University of New Mexico Health Sciences Center, University Medical Center Mainz, and Boston Medical Center.
Strategic Value for Healthcare Stakeholders
The findings support pharmaceutical companies, biotechnology developers, investors, healthcare providers, and market-access teams seeking to understand knee osteoarthritis market opportunities. Epidemiology-based bottom-up forecasting, competitive benchmarking, pipeline prioritization, and expert insights can help stakeholders assess commercial potential, refine clinical development plans, prepare market-entry strategies, and identify opportunities to address persistent gaps in patient care.
With the knee osteoarthritis market forecast to approach USD 26.00 billion by 2036, competition is expected to intensify as established intra-articular products expand their reach and emerging disease-modifying and regenerative candidates advance toward commercialization.
Key Topics Covered
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
4.1. Key Conferences And Meetings
4.2. Key Transactions And Collaborations
4.3. News Flow
5. Epidemiology and Market Methodology of Knee Osteoarthritis
6. Knee Osteoarthritis Market Overview at a Glance
6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
6.2. Market Share of knee osteoarthritis By Therapies (%) in the 7MM in 2025
6.3. Market Share of knee osteoarthritis By Therapies (%) in the 7MM in 2036
7. Disease Background And Overview of Knee Osteoarthritis
7.1. Introduction
7.2. Types of knee osteoarthritis
7.3. Molecular Classification of Knee Osteoarthritis
7.4. Causes
7.5. Signs And Symptoms
7.6. Diagnosis
7.6.1. Differential Diagnosis
7.6.2. Diagnostic Algorithm
7.6.3. Diagnostic Guidelines
7.7. Treatment and Management
7.8. Treatment Algorithm
7.9. Treatment Guidelines
7.9.1. Guidelines for Management of Knee Osteoarthritis (American College of Rheumatology/Arthritis)
7.9.2. Clinical Practice Guidelines for Management of Knee Osteoarthritis (Non-arthroplasty) (American Academy of Orthopedic Surgeons)
7.9.3. Guidelines for Management of Knee Osteoarthritis (European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases)
7.9.4. Guidelines for Management of Knee Osteoarthritis (French Society of Rheumatology)
7.9.5. Clinical Practice Guidelines for Diagnosis and Management of Knee Osteoarthritis (Italian Society for Rheumatology)
7.9.6. Guidelines for Management of Knee Osteoarthritis (National Institute for Health and Care Excellence)
7.9.7. OARSI Guidelines for the Nonsurgical Management of Knee and Hip Osteoarthritis
8. Epidemiology and Patient Population of Knee Osteoarthritis
8.1. Key Findings
8.2. Assumption and Rationale
8.3. Total Prevalent Cases of Knee Osteoarthritis in the 7MM
8.4. The United States
8.4.1. Total Prevalent Cases of Knee Osteoarthritis in the United States
8.4.2. Gender-specific Prevalent Cases of Knee Osteoarthritis in the United States
8.4.3. Age-specific Prevalent Cases of Knee Osteoarthritis in the United States
8.4.4. Severity-specific Prevalent Cases of Knee Osteoarthritis in the United States
8.5. EU4 and the UK
8.5.1. Total Prevalent Cases of Knee Osteoarthritis in EU4 and the UK
8.5.2. Gender-specific Prevalent Cases of Knee Osteoarthritis in EU4 and the UK
8.5.3. Age-specific Prevalent Cases of Knee Osteoarthritis in EU4 and the UK
8.5.4. Severity-specific Prevalent Cases of Knee Osteoarthritis in EU4 and the UK
8.6. Japan
8.6.1. Total Prevalent Cases of Knee Osteoarthritis in Japan
8.6.2. Gender-specific Prevalent Cases of Knee Osteoarthritis in Japan
8.6.3. Age-specific Prevalent Cases of Knee Osteoarthritis in Japan
8.6.4. Severity-specific Prevalent Cases of Knee Osteoarthritis in Japan
9. Patient Journey of Knee Osteoarthritis
10. Marketed Therapies
10.1. Marketed Competitive Landscape of Knee Osteoarthritis
10.2. JOYCLU: Ono Pharmaceutical/Seikagaku
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Other Developmental Activities
10.2.4. Summary of Pivotal Trials
10.2.5. Analyst Views
10.3. TRILURON: Fidia Farmaceutici
10.3.1. Product Description
10.3.2. Regulatory Milestones
10.3.3. Summary of Pivotal Trials
10.3.4. Analyst Views
. List to be continued.
11. Emerging Therapies
11.1. Emerging Competitive Landscape of Knee Osteoarthritis
11.2. ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharma
11.2.1. Product Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Development
11.2.3.1. Clinical Trial Information
11.2.4. Safety and Efficacy
11.2.5. Analyst Views
. List to be continued.
12. Knee Osteoarthritis: Seven Major Market Analysis
12.1. Key Findings
12.2. Market Outlook of Knee Osteoarthritis
12.3. Conjoint Analysis of Knee Osteoarthritis
12.4. Key Market Forecast Assumptions
12.4.1. Cost Assumptions
12.4.2. Pricing Trends
12.4.3. Analogue Assessment
12.4.4. Launch Year and Therapy Uptakes
12.5. Total Market Size of knee osteoarthritis in the 7MM
12.6. The United States
12.6.1. Total Market Size of knee osteoarthritis in the United States
12.6.2. Market Size of Knee Osteoarthritis by Therapies in the United States
12.7. EU4 and the UK
12.7.1. Total Market Size of knee osteoarthritis in EU4 and the UK
12.7.2. Market Size of knee osteoarthritis by Therapies in EU4 and the UK
12.8. Japan
12.8.1. Total Market Size of knee osteoarthritis in Japan
12.8.2. Market Size of Knee Osteoarthritis by Therapies in Japan
13. Unmet Needs of Knee Osteoarthritis
14. SWOT Analysis of Knee Osteoarthritis
15. KOL Views of Knee Osteoarthritis
15.1. Expert/KOL Interview Highlights
16. Market Access and Reimbursement of Knee Osteoarthritis
16.1. The US
16.2. In EU4 and the UK
16.2.1. Germany
16.2.2. France
16.2.3. Italy
16.2.4. Spain
16.2.5. United Kingdom
16.3. Japan
16.4. Summary and Comparison of Market Access and Pricing Policy Developments in 2025
16.5. Market Access and Reimbursement of knee osteoarthritis Therapies
17. Appendix
17.1. Bibliography
17.2. Report Methodology
For more information about this report visit https://www.researchandmarkets.com/r/jmi07u
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.